ClinicalTrials.gg
CompletedNCT05199584Updated Mar 5, 2026

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

A Phase 2 interventional study of ENV-101 (taladegib) in Solid Tumors With PTCH1 Loss-of-function Mutations, sponsored by Endeavor Biomedicines, Inc.. Completed at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by Endeavor Biomedicines, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2024, 2 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 72 studies in Laryngeal Diseases with a site in United States — 15 open to participants now, 17 under way, 3 of them phase 3. Laryngeal Diseases · United States.

Enrollment
44th of 61
20 · median 46
Started
2022
with 1 other
Phase 2
17 of 72
4 open now
Registered
56th of 72
by date

Among the 72 studies in Laryngeal Diseases with a site in United States, this one is the 44th largest by enrollment of the 61 interventional ones that give a count, is one of 2 that started in 2022, is one of 17 in phase 2, and was the 56th registered.

Laryngeal Diseases

147 studies on the registry are indexed under Laryngeal Diseases; 26 are open to participants now.

Browse Laryngeal Diseases studies →

Open to participants now

15 of the 72 studies in Laryngeal Diseases with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 21 Laryngeal Diseases studies recruiting now, 17 (81%) set no upper age limit and 1 (5%) stops at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Laryngeal Diseases with a site in United States, or all of them as a file.
02

Study summary

This study employs a 2-stage design that aims to evaluate the efficacy and safety of ENV- 101, a potent Hedgehog (Hh) pathway inhibitor, in patients with refractory advanced solid tumors characterized by loss of function (LOF) mutations in the Patched-1 (PTCH1) gene. Stage 1 of this study will enroll approximately 44 patients randomized between two dose levels. As appropriate, Stage 2 of the study will expand enrollment based on the results of Stage 1.

03

Conditions studied

  • Solid Tumors With PTCH1 Loss-of-function Mutations

Keywords

  • Patched-1
  • PTCH1
  • Hedgehog inhibitor
  • Smoothened inhibitor
  • Endeavor
  • NGS
  • Next Generation Sequencing
  • Head and Neck
  • Laryngeal
  • Hypopharyngeal
  • Nasal Cavity
  • Nasopharyngeal
  • Oral Cavity
  • Oropharyngeal
  • Throat
  • Salivary Gland
  • Lung
  • Lung Carcinoid
  • Breast
  • Skin
  • Basal
  • Squamous
  • Melanoma
  • Merkel Cell
  • Anal
  • Bile Duct
  • Colorectal
  • Esophagus
  • Gallbladder
  • Gastrointestinal
  • Liver
  • Pancreatic
  • Pancreatic Neuroendocrine Tumor
  • NET
  • Small Intestine
  • Stomach
  • Cervical
  • Endometrial
  • Ovarian
  • Penile
  • Prostate
  • Testicular
  • Uterine
  • Vaginal
  • Vulvar
  • Bone
  • Osteosarcoma
  • Rhabdomyosarcoma
  • Soft Tissue Sarcoma
  • Eye
  • Ocular Melanoma
  • Retinoblastoma
  • Brain
  • Spinal Cord
  • Neuroblastoma
  • Adrenal
  • Pituitary
  • Bladder
  • Kidney
  • Medulloblastoma
  • Glioma
  • Wilms
  • Precision Oncology
  • Mesothelioma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females or males greater than or equal to 18 years of age. If under 18 years of age, males must have a bone age of at least 17 years and females must have a bone age of at least 15 years. X-rays will be reviewed by a qualified physician (e.g. radiologist or endocrinologist) for eligibility for those under 18 years of age
  • Has or cytologically confirmed solid tumor that harbors a PTCH1 loss of function mutation, identified via genomic sequencing routinely performed at a CLIA certified laboratory
  • Able to take medication orally
  • Patients must be to all standard of care therapy, or standard or curative therapy does not exist, or the patient has documented their refusal of standard of care therapies
  • Patients willing to sign and have a full understanding of the form
  • of ≥ 3 months

Exclusion criteria

Exclusion Criteria:

  • Concurrent administration of any anti-cancer therapies (e.g., chemotherapy, other targeted therapy) other than those administered in this study
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures. Patients with indwelling catheters are allowed
  • other than the primary tumor type within 5 years prior to study start, with the exception of those with a negligible risk of or death (e.g., expected 5-year Overall Survival > 90%) treated with expected curative outcome (e.g., in situ melanoma, basal or squamous cell skin cancer if completely excised, localized prostate cancer that is managed by surveillance, ductal carcinoma in situ treated surgically with curative intent are allowed)
  • History of disease requiring prescription systemic therapy in the last two years prior to study start; patients with controlled hypothyroidism may be considered after evaluation by the Investigator.
  • Presence of active infection at study start or confirmed active (HIV), virus (HBV), or virus (HCV)
  • Significant cardiovascular disease, such as cardiac disease (Class II or greater), myocardial infarction within 3 months prior to study start, unstable arrhythmias, or unstable angina. Patients with known coronary artery disease, congestive heart failure not meeting the above criteria, or \< 50% must be on a stable medical regimen that is optimized in the opinion of the treating physician
  • nausea and vomiting, malabsorption, external biliary shunt or significant bowel resection that would preclude adequate absorption of product
  • Major surgical procedure within 28 days prior to study start or anticipation of need for a major surgical procedure during the course of the study
  • Treatment with any other investigational agent or participation in another clinical study with therapeutic intent within 28 days prior to study start
  • Use of drugs that are known moderate or stronger inhibitors or inducers within 12 days prior to study start
  • Unresolved toxicity of ≥ Grade 2 attributed to any prior therapies (excluding anemia, alopecia, skin pigmentation, platinum-induced neurotoxicity and endocrine disease or ailments that are stable)
  • Males and females of who are sexually active and unwilling to use for the duration of the study and for 3 months after their final study dose
  • Females that are pregnant or nursing
  • Females and males that are unwilling to refrain from blood or blood product donation for the duration of the study and for 30 days after their final study dose
  • Males who are unwilling to refrain from sperm donation and females who are unwilling to refrain from egg donation for the duration of the study and for 3 months after their final study dose
  • Patients with a history of a severe allergic reaction, anaphylactic reaction or known to any component of ENV-101
  • Patients who are immediate family members (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with a study investigative site or the study Sponsor
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    200 mg ENV-101

    ENV-101 (taladegib) tablets, 200 mg once-daily in 28-day cycles

    Drug: ENV-101 (taladegib)

  • Experimental
    300 mg ENV-101

    ENV-101 (taladegib) tablets, 300 mg once-daily in 28-day cycles

    Drug: ENV-101 (taladegib)

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR is comprised of Complete Response (CR) and Partial Response (PR), measured by Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1), as determined by an independent review (confirmed CR or PR will be defined as a repeat assessment performed no less than 28 days after the criteria for response is first met).

    Time frame: through study completion, an average of 6 months

Secondary outcomes

  1. Frequency of Adverse Events (AEs)

    Time frame: through study completion, an average of 6 months

  2. Frequency of unacceptable toxicities

    Unacceptable toxicities = non-hematologic AEs \>= Grade 3 in severity, not including alopecia and fatigue.

    Time frame: through study completion, an average of 6 months

  3. ORR by Investigator

    Best overall response of confirmed CR or PR as determined by the treating Investigator using RECIST 1.1.

    Time frame: through study completion, an average of 6 months

  4. Clinical Benefit Rate (CBR)

    CBR = the proportion of patients who achieved CR, PR or stable disease as determined by the treating Investigator using RECIST 1.1.

    Time frame: through study completion, an average of 6 months

  5. Overall Survival (OS)

    OS = Number of months from initiation of study medication to the date of death due to any cause or last follow up.

    Time frame: through study completion, an average of 6 months

  6. Duration of Response (DOR)

    DOR = the number of months from the start of CR or PR, whichever response is recorded first and subsequently confirmed, to the first date that recurrent or progressive disease is documented or death.

    Time frame: through study completion, an average of 6 months

  7. Progression Free Survival (PFS)

    PFS = number of months from initiation of study medication to the earlier of disease progression or death due to any cause or last follow up.

    Time frame: through study completion, an average of 6 months

  8. Change in Gli1 inhibition

    Percentage change in inhibition of Gli1, a marker for inhibition of the Hedgehog pathway, in skin biopsies.

    Time frame: From Baseline through study completion, an average of 6 months

  9. Change in steady-state exposure to study medication

    Measurement of trough concentration of study medication in blood at Baseline and the end of each 28-day treatment cycle

    Time frame: From Baseline through study completion, an average of 6 months

07

Study locations

16 sites
  • Research Site
    Los Angeles, California 90095, United States
  • Research Site
    Santa Rosa, California 95403, United States
  • Research Site
    Tampa, Florida 33609, United States
  • Research Site
    Zion, Illinois 60099, United States
  • Research Site
    Covington, Louisiana 70433, United States
  • Research Site
    Las Vegas, Nevada 89102, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Durham, North Carolina 27710, United States
  • Research Site
    Cincinnati, Ohio 45229, United States
  • Research Site
    Columbus, Ohio 43210, United States
  • Research Site
    Pittsburgh, Pennsylvania 15232, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Fredericksburg, Virginia 22408, United States
  • Research Site
    Lynchburg, Virginia 24501, United States
  • Research Site
    Madison, Wisconsin 53792, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2022 to primary completion in Feb 2024, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2021
First posted
Jan 20, 2022
StartActual
May 24, 2022
Primary completionActual
Feb 20, 2024
CompletionActual
Feb 20, 2024
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05199584
Lead sponsor
Endeavor Biomedicines, Inc.
Responsible party
Sponsor
First posted
Jan 20, 2022
Start date
May 24, 2022
Primary completion
Feb 20, 2024
Completion
Feb 20, 2024
Last update
Mar 5, 2026

Study contacts

Lisa Lancaster, M.D.
study director · Endeavor Biomedicines

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LY2940680

Start the discussion